• Retains tissue-protective effects of EPO without blood-thickening.
• Targets localized inflammation and promotes tissue repair.
• Studied for its potential in neuroprotection and pain management.
• Specific agonist for the Innate Repair Receptor (IRR).
• Tool for research into regenerative medicine and immunology.

ARA 290 is a modified peptide derived from erythropoietin (EPO) that is specifically designed to retain EPO's tissue-protective and anti-inflammatory effects while avoiding its strong blood-thickening properties. This allows for targeted tissue protection without raising red blood cell counts.

ARA 290 (Cibinetide) is an 11-amino acid peptide based on the structure of erythropoietin. It binds specifically to the Innate Repair Receptor (IRR), a heterodimer of the EPO receptor and the beta common receptor (CD131). This receptor is primarily expressed in response to tissue stress and injury, triggering protective and anti-inflammatory pathways.

Research focuses on ARA 290's potential to protect and repair damaged tissues, particularly in the context of nerve-related inflammation and neuropathic pain. Its ability to activate innate repair pathways without erythropoietic side effects makes it a valuable subject for regenerative medicine and immunology studies.